Susanna Schraen

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study

Julien Dumurgier, Susanna Schraen, Audrey Gabelle et al. · Alzheimer s Research & Therapy · 2015 · 136 citations · Full text

Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview

Constance Delaby, Charlotte E. Teunissen, Kaj Blennow et al. · Alzheimer s & Dementia · 2021 · 55 citations · Full text

Plasma amyloid β levels are driven by genetic variants near <i>APOE, BACE1, APP, PSEN2</i>: A genome‐wide association study in over 12,000 non‐demented participants

Vincent Damotte, Sven J. van der Lee, Vincent Chouraki et al. · Alzheimer s & Dementia · 2021 · 39 citations · Full text

What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France

Emmanuel Cognat, François Mouton‐Liger, Anne‐Cécile Troussière et al. · BMJ Open · 2019 · 26 citations · Full text

Response to pneumococcal vaccination in multiple myeloma

Loïc Renaud, Susanna Schraen, Guillemette Fouquet et al. · Cancer Medicine · 2019 · 24 citations · Full text